Review
Open access
Aug 2026
Isocitrate dehydrogenase (IDH) as target for anticancer therapy in brain and gastrointestinal cancers
The characteristics of the FDA-approved and other investigational IDH-targeted drugs are described, evaluating the most recent clinical studies on targeting IDH genomic alterations in the treatment of gliomas and cholangiocarcinoma.
Virginia Agnetti, Alessandro Acunzo, Giulia Airò et al.
· Discover medicine · 0 citations